Company intelligence / Profile preview
InterAx Biotech AG
Villigen, Aargau, Switzerlandinteraxbiotech.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Other
01
Overview
InterAx’s lead program in immuno-oncology has demonstrated reversal of tumor immune evasion by restoring intra-tumoral cytokine levels and recruiting cancer-killing cells, resulting in significant tumor regression in preclinical models. Their metabolic disease programs are developing oral alternatives to injectable GLP‑1/GIP therapies with promising efficacy and improved tolerability profiles. No clinical data reported yet.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Small moleculesPeptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Boehringer IngelheimLundbeckGPCR TherapeuticsEU Commission grants
Beyond the preview
Go deeper on InterAx Biotech AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InterAx Biotech AG.